FibroBiologics (FBLG) Convertible Debt (2022)
FibroBiologics' (FBLG) quarterly Convertible Debt came in at $5.6 million in Q4 2022.
Powered by 
Analysis
FibroBiologics (FBLG) Convertible Debt (2022) Analysis & Trends
FibroBiologics (FBLG) has reported Convertible Debt for 1 consecutive years, with $5.6 million the latest figure, recorded in Q4 2022.
- For the quarter ending Q4 2022, Convertible Debt changed N/A year-over-year to $5.6 million; the trailing twelve-month figure through Dec 2022 stood at $5.6 million (changed N/A YoY), and the FY2022 full-year result was $5.6 million, changed N/A from the prior year.
- Convertible Debt steadied at $5.6 million in Q4 2022 per FBLG's latest filing.
- Across five years, Convertible Debt topped out at $5.6 million in Q4 2022 and bottomed at $5.6 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn |
| 10 | FibroBiologics | 10.91 Mn | 10.91 Mn | - |